Drug Trial Radar · NCT05490017
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104
Last checked: Nov 19, 2026Latest source record: Mar 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Dec 30, 2020
Primary completion
May 4, 2022
Study completion Sep 2, 2022
Sponsor
- Lead sponsor
- Kira Pharmacenticals (US), LLC.Industry
- Sponsor type
- Industry
- First posted
- Aug 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of KP104 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of KP104 and Part 2, multiple ascending dose (MAD).
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
KP104Drug
Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.
PlaceboDrug
Participants will receive matching placebo which is KP104 vehicle containing sodium phosphate, sodium chloride, and L-Lysine Hydrochloride (L-Lys-HCL).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants reporting Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 85
- Number of participants reporting Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Up to Day 85
- Number of participants with Dose-limiting toxicities (DLT)Time frame: Up to Day 85
- Number of participants reporting AEs of Special interests (AESIs)Time frame: Up to Day 85
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.